• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Osteonecrosis of the jaw in a patient on Denosumab.使用地诺单抗治疗的患者发生颌骨坏死。
J Oral Maxillofac Surg. 2010 May;68(5):959-63. doi: 10.1016/j.joms.2009.10.010. Epub 2010 Feb 10.
2
Stage 0 osteonecrosis of the jaw in a patient on denosumab.使用地诺单抗治疗的患者发生颌骨0期骨坏死。
J Oral Maxillofac Surg. 2014 Apr;72(4):702-16. doi: 10.1016/j.joms.2013.09.008. Epub 2014 Jan 4.
3
Denosumab-related osteonecrosis of the jaws.地诺单抗相关的颌骨坏死。
Osteoporos Int. 2011 Jan;22(1):369-70. doi: 10.1007/s00198-010-1177-6. Epub 2010 Mar 20.
4
Osteonecrosis of the jaw after zoledronic acid and denosumab treatment.唑来膦酸和地诺单抗治疗后颌骨骨坏死
J Clin Oncol. 2011 Jun 10;29(17):e521-2; author reply e523-4. doi: 10.1200/JCO.2011.35.1551. Epub 2011 May 2.
5
Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab.接受地舒单抗治疗的男性骨质疏松症患者发生下颌骨坏死。
Osteoporos Int. 2014 Jan;25(1):393-5. doi: 10.1007/s00198-013-2437-z. Epub 2013 Jul 9.
6
Osteonecrosis of the jaw.颌骨骨坏死
Endokrynol Pol. 2011 Jan-Feb;62(1):88-92.
7
More about osteonecrosis.更多关于骨坏死的信息。
J Am Dent Assoc. 2011 Apr;142(4):371-2; author reply 372-4. doi: 10.14219/jada.archive.2011.0183.
8
New oncology drugs and osteonecrosis of the jaw (ONJ).新型肿瘤药物与颌骨骨坏死（ONJ）
J Tenn Dent Assoc. 2009 Fall;89(4):36-8; quiz 38-9.
9
A new class of drugs to prevent osteoporosis may be associated with osteonecrosis of the jaw.一类预防骨质疏松症的新型药物可能与颌骨坏死有关。
Gen Dent. 2011 Jan-Feb;59(1):10-2.
10
Osteonecrosis of the jaw and the role of macrophages.颌骨骨坏死与巨噬细胞的作用。
J Natl Cancer Inst. 2011 Feb 2;103(3):232-40. doi: 10.1093/jnci/djq516. Epub 2010 Dec 28.

引用本文的文献

1
Identifying a predictive level of serum C-terminal telopeptide associated with a low risk of medication-related osteonecrosis of the jaw secondary to oral surgery: A systematic review and meta-analysis.确定与口腔手术后颌骨药物相关性骨坏死低风险相关的血清C末端肽预测水平：一项系统评价和荟萃分析。
PLoS One. 2025 May 5;20(5):e0318260. doi: 10.1371/journal.pone.0318260. eCollection 2025.
2
Mechanisms Underlying Medication-Related Osteonecrosis of the Jaw.颌骨药物相关性骨坏死的潜在机制
Oral Dis. 2025 Apr;31(4):1073-1083. doi: 10.1111/odi.15198. Epub 2024 Nov 18.
3
The role of leukocyte and platelet-rich fibrin in the prevention of medication-related osteonecrosis of the jaw, in patients requiring dental extractions: an observational study.富含白细胞和血小板纤维蛋白在预防拔牙患者药物相关性颌骨坏死中的作用：一项观察性研究。
Oral Maxillofac Surg. 2024 Jun;28(2):785-793. doi: 10.1007/s10006-023-01204-z. Epub 2024 Jan 6.
4
Medication-Related Osteonecrosis of the Jaw: A Systematic Review and a Bioinformatic Analysis.药物相关性颌骨坏死：系统评价与生物信息学分析。
Int J Mol Sci. 2023 Nov 25;24(23):16745. doi: 10.3390/ijms242316745.
5
Management of a rare mandibular giant cell tumor of bone by neoadjuvant denosumab therapy and surgery: A 4-year follow-up case report.通过新辅助地诺单抗治疗和手术治疗罕见的下颌骨巨细胞瘤：一例4年随访病例报告
Int J Surg Case Rep. 2023 Nov;112:108980. doi: 10.1016/j.ijscr.2023.108980. Epub 2023 Oct 30.
6
Anti-resorptive therapy in the osteometabolic patient affected by periodontitis. A joint position paper of the Italian Society of Orthopaedics and Traumatology (SIOT) and the Italian Society of Periodontology and Implantology (SIdP).抗吸收治疗在患有牙周炎的骨代谢患者中的应用。意大利矫形外科和创伤学会（SIOT）与意大利牙周病学和种植学会（SIdP）的联合立场文件。
J Orthop Traumatol. 2023 Jul 15;24(1):36. doi: 10.1186/s10195-023-00713-7.
7
Denosumab-associated jaw bone necrosis in cancer patients: retrospective descriptive case series study.癌症患者中与地诺单抗相关的颌骨坏死：回顾性描述性病例系列研究
Maxillofac Plast Reconstr Surg. 2023 Jun 30;45(1):23. doi: 10.1186/s40902-023-00391-9.
8
Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan.台湾多机构回顾性队列研究：比较接受双膦酸盐和地舒单抗治疗的骨质疏松症患者颌骨坏死的风险。
Osteoporos Int. 2023 Oct;34(10):1729-1737. doi: 10.1007/s00198-023-06818-3. Epub 2023 Jun 16.
9
Evaluation of the anti-RANKL monoclonal antibody in rheumatoid arthritis rats.抗RANKL单克隆抗体在类风湿性关节炎大鼠中的评估。
Arch Rheumatol. 2022 Nov 4;38(1):22-31. doi: 10.46497/ArchRheumatol.2023.9240. eCollection 2023 Mar.
10
Complications and prognosis of primary thoracic and lumbar giant cell tumors treated by total tumor resection.原发性胸腰椎巨细胞瘤全切除术后的并发症和预后。
BMC Musculoskelet Disord. 2023 Apr 12;24(1):281. doi: 10.1186/s12891-023-06347-4.

本文引用的文献

1
Emerging treatments for postmenopausal osteoporosis - focus on denosumab.绝经后骨质疏松症的新兴治疗方法——聚焦地舒单抗。
Clin Interv Aging. 2009;4:241-50. doi: 10.2147/cia.s3333. Epub 2009 Jun 9.
2
Giant cell tumour of bone.骨巨细胞瘤
Curr Opin Oncol. 2009 Jul;21(4):338-44. doi: 10.1097/CCO.0b013e32832c951d.
3
Denosumab update.地诺单抗最新情况
Curr Opin Rheumatol. 2009 Jul;21(4):369-73. doi: 10.1097/BOR.0b013e32832ca41c.
4
The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data.双膦酸盐相关颌骨坏死的发病机制：假说众多，数据匮乏。
J Oral Maxillofac Surg. 2009 May;67(5 Suppl):61-70. doi: 10.1016/j.joms.2009.01.007.
5
American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update.美国口腔颌面外科医师协会关于双膦酸盐相关颌骨坏死的立场文件——2009年更新版
J Oral Maxillofac Surg. 2009 May;67(5 Suppl):2-12. doi: 10.1016/j.joms.2009.01.009.
6
Clinical applications of RANK-ligand inhibition.RANK 配体抑制的临床应用。
Intern Med J. 2009 Feb;39(2):110-6. doi: 10.1111/j.1445-5994.2008.01732.x.
7
Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.地诺单抗用于接受静脉双膦酸盐治疗后的前列腺癌、乳腺癌或其他肿瘤骨转移患者的随机II期试验。
J Clin Oncol. 2009 Apr 1;27(10):1564-71. doi: 10.1200/JCO.2008.19.2146. Epub 2009 Feb 23.
8
Osteonecrosis related to intraosseous anesthesia: report of a case.骨内麻醉相关的骨坏死：一例报告。
J Endod. 2009 Feb;35(2):288-91. doi: 10.1016/j.joen.2008.11.002. Epub 2008 Dec 12.
9
Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy.地诺单抗在未接受过双膦酸盐治疗的骨转移乳腺癌患者中的疗效和安全性扩展研究
Clin Cancer Res. 2008 Oct 15;14(20):6690-6. doi: 10.1158/1078-0432.CCR-07-5234.
10
Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial.地诺单抗与阿仑膦酸钠对低骨量绝经后妇女骨密度及骨转换生化标志物影响的比较：一项随机、双盲、3期试验
J Bone Miner Res. 2009 Jan;24(1):153-61. doi: 10.1359/jbmr.0809010.

Osteonecrosis of the jaw in a patient on Denosumab.

作者信息

Aghaloo Tara L, Felsenfeld Alan L, Tetradis Sotirios

机构信息

Section of Oral and Maxillofacial Surgery, School of Dentistry, University of California, Los Angeles, Los Angeles, CA 90095, USA.

出版信息

J Oral Maxillofac Surg. 2010 May;68(5):959-63. doi: 10.1016/j.joms.2009.10.010. Epub 2010 Feb 10.

DOI:10.1016/j.joms.2009.10.010
PMID:20149510
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2880179/
Abstract
摘要